HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hendrikx, M. Articles by Mees, U. Search for Related Content PubMed PubMed Citation Articles by Hendrikx, M. Articles by Mees, U. Related Collections Cardiac - pharmacology Minimally invasive surgery

Eur J Cardiothorac Surg 2001;19:633-639
© 2001 Elsevier Science NL

Na⁺/H⁺-exchange inhibition and aprotinin administration: promising tools for myocardial protection during minimally invasive CABG

^a Limburgs Universitair Centrum, Universitaire Campus, 3590 Diepenbeek, Belgium
^b Department of Cardiothoracic and Vascular Surgery, Virga Jesse Hospital, B-3500 Hasselt, Belgium
^c Department of Cardiac Anaesthesiology, Virga Jesse Hospital, Stadsomvaart 11, B-3500 Hasselt, Belgium

Received 9 October 2000; received in revised form 1 February 2001; accepted 22 February 2001.

Corresponding author. Department of Cardiothoracic and Vascular Surgery, Virga Jesse Hospital, B-3500 Hasselt, Belgium. Tel.: +32-11-309060; fax: +32-11-309068
e-mail: marc.hendrikx{at}virgajesse.be

Objective: Minimally invasive coronary artery bypass grafting (CABG), carried out on the warm beating heart, does not allow conventional myocardial protection. The objective was to investigate the possibility of enhancing tolerance to ischemia during short episodes of coronary artery occlusion, based on a pharmacological approach using a selective Na⁺/H⁺-exchange inhibitor (cariporide) or a serine protease inhibitor (aprotinin). Methods: Four groups (n=6 in each group) of sheep were subjected to 20 min of normothermic regional ischemia (first lateral branch of the circumflex artery occlusion) followed by 1 h of reperfusion. Regional wall thickening was measured using sonomicrometry, and expressed as the percentage of thickening fraction compared with baseline. Group I was the control with no treatment, group II received cariporide (1 mg/kg administered over 2 min prior to ischemia), group III was treated with aprotinin (2.10⁶ kallikrein inactivation units (KIU) load followed by 500.000 KIU/h). Group IV was treated with a combination of cariporide and aprotinin at the same concentrations as in groups II and III, respectively. Results: Wall thickening measurements showed that, compared with control, cariporide was largely able to suppress secondary loss of wall thickening after initial recovery during early reperfusion. Wall thickening in the ischemic/reperfused myocardial area improved from 10±31 to 51±17% at 1 h of reperfusion (P=0.002). Aprotinin improved wall thickening at the end of 1 h of reperfusion to 70±13% (P=0.0001). However, in this group, there was a transient loss of regional contractility similar in amplitude and time course to the one observed in the control group. A combination of cariporide and aprotinin suppressed transient contractile loss and resulted in improved wall thickening at the end of 1 h of reperfusion (65±22%, P=0.0002 vs. control). This value was not significantly different from the cariporide (P=0.263) or aprotinin (P=0.704) group. Conclusion: These data indicate that both Na⁺/H⁺-exchange inhibition and aprotinin administration are promising tools for cardioprotection during minimally invasive CABG. A combination of both treatments is able to adequately suppress loss of contractility during early reperfusion as a consequence of reperfusion injury, and results in significantly improved wall thickening at the end of 1 h of reperfusion.

Key Words: Beating heart surgery • Myocardial protection • Na⁺/H⁺-exchange inhibition • Aprotinin

This article has been cited by other articles:

				M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]

				A. Sedrakyan, A. Wu, G. Sedrakyan, M. Diener-West, M. Tranquilli, and J. Elefteriades Aprotinin use in thoracic aortic surgery: Safety and outcomes J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 909 - 917. [Abstract] [Full Text] [PDF]

				T. A. Khan, C. Bianchi, P. Voisine, J. Feng, J. Baker, M. Hart, M. Takahashi, G. Stahl, and F. W. Sellke Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 602 - 608. [Abstract] [Full Text] [PDF]

				R. M. Stevens, M. Salik Jahania, R. M. Mentzer Jr, and R. D. Lasley Sodium-hydrogen exchange inhibition attenuates in vivo porcine myocardial stunning Ann. Thorac. Surg., February 1, 2004; 77(2): 651 - 657. [Abstract] [Full Text] [PDF]

				A. H Olivencia-Yurvati, N. Wallace, S. Ford, and R. T Mallet Leukocyte filtration and aprotinin: synergistic anti-inflammatory protection Perfusion, January 1, 2004; 19(1_suppl): S13 - S19. [Abstract] [PDF]

				D. A. Bull and J. Maurer Aprotinin and preservation of myocardial function after ischemia-reperfusion injury Ann. Thorac. Surg., February 1, 2003; 75(2): S735 - 739. [Abstract] [Full Text] [PDF]

				R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438. [Full Text]